NCT06682637

Melflufen for Elderly Patients With Relapsed Myeloma

Melflufen for Elderly Myeloma Patients in Second or Subsequent Relapse

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Fondazione EMN Italy Onlus · Academic / Other
• Sex: All
• Age: 70 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse. Thirty elderly patients at second or subsequent relapse.

Conditions

• Relapse Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Melflufen	Pepaxti 20 mg powder for concentrate for solution for infusion
DRUG	Dexamethasone	SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution

Timeline

• Start date: 2025-03-26
• Primary completion: 2025-03-26
• Completion: 2025-03-26
• First posted: 2024-11-12
• Last updated: 2025-04-01

Locations

10 sites across 1 country: Italy